Disease relevance of Loiasis

• Five cases of encephalitis during treatment of loiasis with diethylcarbamazine [1].

High impact information on Loiasis

• Diethylcarbamazine and human loiasis [2].
• Mebendazole treatment of loaiasis [3].
• To study immune mechanisms controlling microfilaremia, sera from 15 subjects with amicrofilaremic occult loiasis (OL) were compared with sera from 10 subjects with microfilaremic loiasis (ML) microfilaremia, (greater than 4000/ml) for their reactions with living microfilariae (mf) [4].
• Doxycycline and eradication of microfilaremia in patients with loiasis [5].
• Albendazole in human loiasis: results of a double-blind, placebo-controlled trial [6].

Chemical compound and disease context of Loiasis

• The importance of the 29-31 kDa glycoprotein in the immunobiology of loaiasis is suggested by the finding that resistant and infected amicrofilaremic individuals have strongly reactive IgG antibodies to this antigen [7].
• Species-specific sequence in the repeat 3 region of the gene encoding a putative Loa loa allergen: a diagnostic tool for occult loiasis [8].

Gene context of Loiasis

• Human occult loiasis: improvement in diagnostic sensitivity by the use of a nested polymerase chain reaction [9].
• No relation was found between the ABO blood groups and loiasis [10].

Analytical, diagnostic and therapeutic context of Loiasis

• Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind study [11].
• Although successful treatment of loiasis with diethylcarbamazine (DEC) has been reported, little is known about the long-term success rate of therapy or the predisposing factors for treatment failure [12].
• Immunoprecipitation with occult and microfilaremic loaiasis sera demonstrated that the 23 kDa surface molecule and excretory-secretory products of 14.4 and 33 kDa were only recognized by occult loaiasis sera whereas surface molecules of 40 and 75-84 kDa and excretory-secretory products of 28 and 67 kDa were recognised by both sera [13].

References